Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
J Control Release. 2018 Jan 28;270:14-22. doi: 10.1016/j.jconrel.2017.11.028. Epub 2017 Nov 21.
Thermodynamically and chemically stable RNA nanoparticles derived from the three-way junction (3WJ) of the pRNA from bacteriophage phi29 DNA packaging motor were examined previously for ocular delivery. It was reported that, after subconjunctival injection, RNA nanoparticles with tri-way shape entered the corneal cells but not the retinal cells, whereas particle with four-way shape entered both corneal and retinal cells. The present study evaluated ocular delivery of RNA nanoparticles with various shapes and sizes, and assessed the effect of thermosensitive hydrogels (poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing the retention of RNA nanoparticles in the eye. Fluorescence imaging of mouse eyes and fluorescence microscopy of dissected eye tissues from the conjunctiva, cornea, retina, and sclera were performed to determine the distribution and clearance of the nanoparticles in the eyes after subconjunctival injection in vivo. RNA nanoparticles entered the cells of the conjunctiva, cornea, retina, and sclera after subconjunctival delivery. The clearance of RNA pentagon was slower than both RNA square and triangle of the same designed edge length (10nm) in the eye, and the clearance of RNA squares of the longer edge lengths (10 and 20nm) was slower than RNA square of the shorter edge length (5nm), thus indicating that the size could affect ocular pharmacokinetics of the nanoparticles. At 24h after the injection, approximately 6-10% of the fluorescence signal from the larger nanoparticles in the study (RNA square of 20nm edge length and RNA pentagon of 10nm edge length) remained in the eye, and up to 70% of the retinal cells contained the nanoparticles. The results suggest that the larger nanoparticles were "gulped" in conjunctival, corneal, retinal, and scleral cells, similar to the behavior observed in macrophages. Additionally, the combination of RNA nanoparticles with the thermosensitive polymers increased the retention of the nanoparticles in the eye.
先前已有研究考察了来源于噬菌体 phi29 DNA 包装马达 pRNA 三链结(3WJ)的热力学和化学稳定的 RNA 纳米颗粒在眼部递药中的应用。据报道,经结膜下注射后,具有三向形状的 RNA 纳米颗粒进入角膜细胞但不进入视网膜细胞,而具有四向形状的颗粒则进入角膜和视网膜细胞。本研究评估了不同形状和大小的 RNA 纳米颗粒的眼部递药,并评估了温敏水凝胶(聚(乳酸-共-乙醇酸)-b-聚乙二醇-b-聚(乳酸-共-乙醇酸);PLGA-PEG-PLGA)对增加 RNA 纳米颗粒在眼部滞留的效果。通过对活体小鼠眼部荧光成像和结膜、角膜、视网膜和巩膜组织的荧光显微镜检查,确定了经结膜下注射后纳米颗粒在眼部的分布和清除情况。经结膜下给药后,RNA 纳米颗粒进入结膜、角膜、视网膜和巩膜细胞。在眼部,RNA 五边形的清除速度比具有相同设计边长(10nm)的 RNA 正方形和三角形都慢,而较长边长(10nm 和 20nm)的 RNA 正方形的清除速度比较短边长(5nm)的 RNA 正方形慢,表明尺寸可能会影响纳米颗粒的眼部药代动力学。在注射后 24 小时,研究中较大纳米颗粒(边长为 20nm 的 RNA 正方形和边长为 10nm 的 RNA 五边形)的约 6-10%荧光信号仍保留在眼部,多达 70%的视网膜细胞含有纳米颗粒。结果表明,较大的纳米颗粒被结膜、角膜、视网膜和巩膜细胞“吞噬”,类似于在巨噬细胞中观察到的行为。此外,RNA 纳米颗粒与温敏聚合物的结合增加了纳米颗粒在眼部的滞留。